Valiant Laboratories Balance Sheet Health
Financial Health criteria checks 5/6
Valiant Laboratories has a total shareholder equity of ₹1.1B and total debt of ₹608.7M, which brings its debt-to-equity ratio to 57.7%. Its total assets and total liabilities are ₹2.2B and ₹1.1B respectively. Valiant Laboratories's EBIT is ₹205.1M making its interest coverage ratio -109.3. It has cash and short-term investments of ₹192.4M.
Key information
57.7%
Debt to equity ratio
₹608.70m
Debt
Interest coverage ratio | -109.3x |
Cash | ₹192.35m |
Equity | ₹1.06b |
Total liabilities | ₹1.10b |
Total assets | ₹2.15b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: VALIANTLAB's short term assets (₹1.3B) exceed its short term liabilities (₹480.7M).
Long Term Liabilities: VALIANTLAB's short term assets (₹1.3B) exceed its long term liabilities (₹615.5M).
Debt to Equity History and Analysis
Debt Level: VALIANTLAB's net debt to equity ratio (39.4%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if VALIANTLAB's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: VALIANTLAB's debt is well covered by operating cash flow (69.6%).
Interest Coverage: VALIANTLAB earns more interest than it pays, so coverage of interest payments is not a concern.